US Stock MarketDetailed Quotes
IMRN Immuron
- 1.960
- -0.035-1.75%
Close Dec 20 16:00 ET
11.17MMarket Cap-2.59P/E (TTM)
2.015High1.860Low4.43KVolume1.970Open1.995Pre Close8.55KTurnover0.09%Turnover RatioLossP/E (Static)5.70MShares5.96052wk High1.41P/B9.55MFloat Cap1.59052wk Low--Dividend TTM4.87MShs Float28.990Historical High--Div YieldTTM7.77%Amplitude1.390Historical Low1.927Avg Price1Lot Size
Immuron Stock Forum
Sign in to post a comment
2
1
$Immuron (IMRN.US)$ Trading Halt: Halt Status Updated at 7:45:00 AM ET: Quotation Resumption: News and Resumption Times trading at 7:50 AM
1
$Immuron (IMRN.US)$ NMRC Reports Results for Campylobacter Controlled Human Infection Model Study
Melbourne, Australia, October 4, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN), is an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases. Following discussion with the US Naval Medical Research Command (NMRC), today the Company can announce that ...
Melbourne, Australia, October 4, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN), is an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases. Following discussion with the US Naval Medical Research Command (NMRC), today the Company can announce that ...
3
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Immuron (IMRN.US)$ secured guidance from the US Food and Drug Administration related to the development of its gastrointestinal product IMM-529 to treat infection caused by the bacteria Clostridioides difficile, according to a Thursday filing with the Australian bourse.
The feedback from the meeting will be used for an upcoming investigational new drug application by the first half of 2025 which will be followed by a phase two trial, the biopharmaceutical firm said in th...
The feedback from the meeting will be used for an upcoming investigational new drug application by the first half of 2025 which will be followed by a phase two trial, the biopharmaceutical firm said in th...
No comment yet
Heat List
US
Overall
Symbol
Price
% Chg
No Data
Zipperlips : In January, New York City sued LuxUrban for operating “illegal transient occupancies” in “apartments that can only legally be advertised and used as permanent residences,” which resulted in a $1.2 million fine. This spring, class action lawsuits were opened on behalf of the company's investors, according to reports.Jun 7, 2024
https://www.hoteldive.com › news
LuxUrban Hotels continues leadership shakeups amid lawsuit woes